HealthEquity Stock Climbs After Q2 Earnings Report: Here's Why

HealthEquity (HQY) reported robust second-quarter results, with adjusted EPS of $1.08 and revenue of $325.83 million, both surpassing analyst estimates. The company demonstrated strong operational growth, increasing HSA accounts by 6% to 10.0 million and total HSA assets by 12% to $33.1 billion, while achieving record gross margins of 71% and adjusted EBITDA of $151 million. Driven by this performance and legislative support for HSAs, HQY raised its fiscal 2026 adjusted EPS and revenue guidance, prompting a 4.66% increase in its stock during after-hours trading.

Analysis

HealthEquity, Inc. (HQY) reported a robust second quarter, delivering significant beats on both top and bottom lines. Adjusted earnings per share came in at $1.08, substantially exceeding the consensus estimate of 92 cents, while quarterly revenue of $325.83 million surpassed the $320.82 million forecast. The company's operational momentum is evident in its key performance indicators, with a 6% increase in Health Savings Accounts (HSAs) to 10.0 million and a more pronounced 12% growth in total HSA assets to $33.1 billion. This performance translated into record profitability, with gross margins reaching 71% and adjusted EBITDA hitting a record $151 million on 9% revenue growth, demonstrating strong operating leverage. Management's confidence is further underscored by an upward revision to its fiscal 2026 guidance; the adjusted EPS forecast was raised to a range of $3.74 to $3.91, placing it above the prior $3.72 estimate, while the revenue outlook was reaffirmed around the $1.3 billion consensus. The positive outlook is also supported by CEO Scott Cutler's commentary on a favorable legislative environment, citing the largest expansion of HSAs since 2006 as a key future tailwind. The market reacted favorably to the comprehensive beat-and-raise, with the stock climbing 4.66% in after-hours trading.

Key Decisions for Investors

• Given the significant earnings beat, record profitability, and upwardly revised full-year guidance, these results serve as strong validation for a bullish thesis centered on the secular growth of health savings accounts.
• Investors should monitor the continued growth of total HSA assets, which at 12% is outpacing account growth, as this trend is a key indicator of higher average balances and a primary driver for future revenue.
• Considering the stock's 4.66% post-earnings appreciation, it is prudent to evaluate the company's valuation against the new, higher FY26 EPS guidance of $3.74-$3.91 to assess whether the positive developments are fully reflected in the current price.